Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Phase II Study of Biaxin, Revlimid, and Dexamethasone for Untreated Multiple Myeloma

The recruitment status of this study is unknown because the information has not been verified recently.
Verified December 2009 by Weill Medical College of Cornell University.
Recruitment status was  Active, not recruiting
Sponsor:
Collaborator:
Celgene Corporation
Information provided by:
Weill Medical College of Cornell University
ClinicalTrials.gov Identifier:
NCT00151203
First received: September 6, 2005
Last updated: December 18, 2009
Last verified: December 2009